In Vitro Potential Virucidal Effect Evaluation of Xibornol on Human Adenovirus Type 5, Human Rhinovirus Type 13, Human Coronavirus 229E, Human Parainfluenza Virus Type 1, and Human Respiratory Syncytial Virus.
Cell culture tests
Respiratory viruses
Upper respiratory tract diseases
Virucidal activity
Xibornol
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
7
6
2023
pubmed:
15
6
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
The availability of virucidal compounds to reduce the impact of respiratory viruses is a relevant topic for public health, especially during the recent coronavirus disease (COVID-19) pandemic. Antimicrobial properties of Xibornol are known since the 1970s, but its activity on viruses is currently little explored. In this study, Xibornol activity at a fixed concentration of 0.03 mg/100 ml has been evaluated on five respiratory viruses (Human Adenovirus 5, Human Rhinovirus type 13, Human Coronavirus 229E, Human Parainfluenza Virus type 1, and Human Respiratory Syncytial Virus) through in vitro experiments based on adapted European standard UNI EN 14476-20019. The experiments were carried out under two different environmental conditions, one with the addition of fetal bovine serum to simulate an in vivo condition (dirty condition) and the other without the addition of any organic substances (clean condition). The viral abatement of Xibornol (expressed as Log
Identifiants
pubmed: 35699841
doi: 10.1007/5584_2022_722
doi:
Substances chimiques
xibornol
RQ12GMY0FZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-28Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Bigini C (2019) Patent US20190336456 – Use of xibornol as active agent in the treatment of viral infections
Capponi M (1969) Action de l’isobornyl-6-dimethyl-3-4-phenol Sur le rickettsies pathogenes. Bull Ste Path exotique 62:658–661
Carducci A, Battistini R, Rovini E et al (2009) Viral removal by wastewater treatment: monitoring of indicators and pathogens. Food Environ Virol 1:85–91
doi: 10.1007/s12560-009-9013-x
Celandroni F, Mazzantini D, Calvigioni M et al (2021) Antimicrobial activity of Xibornol and a Xibornol-based formulation against gram-positive pathogens of the respiratory tract. Adv Exp Med Biol. https://doi.org/10.1007/5584_2021_664
Cirri M, Mura P, Mora PC (2007) Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm 340:84–91
doi: 10.1016/j.ijpharm.2007.03.021
pubmed: 17531411
Combe J, Simonnet F, Simonnet G (1988) Action of xibornol on cell division and macromolecular synthesis of gram-positive bacterias. Ann Pharm Fr 46(1):19–26
pubmed: 3146238
Damery B, Cremieux A (1989) Virucidal activity against herpes and Vaccina virus of 8 antiseptic formulations. Int J Pharm 49:205–208
doi: 10.1016/0378-5173(89)90343-8
Elrobaa IH, New KJ (2021) COVID-19: pulmonary and extra pulmonary manifestations. Front Public Health 9:711616
doi: 10.3389/fpubh.2021.711616
pubmed: 34650947
pmcid: 8505777
Fabbri A, Tacchella A, Belli ML (1988) Activity of xibornol against Staphylococcus aureus. Int J Med Soc Chem 7:86–88
Firquet S, Beaujard S, Lobert PE et al (2015) Survival of enveloped and non-enveloped viruses on inanimate surfaces. Microbes Environ 30(2):140–144
doi: 10.1264/jsme2.ME14145
pubmed: 25843687
pmcid: 4462923
Hamilton MA, Russo RC, Thurston RV (1977) Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 11:714–719
doi: 10.1021/es60130a004
Henrickson KJ (2003) Parainfluenza Viruses. Clin Microbiol Rev 16(2):242–264
doi: 10.1128/CMR.16.2.242-264.2003
pubmed: 12692097
pmcid: 153148
Hodinka RL (2016) Respiratory RNA viruses. Microbiol Spectr 4(4)
Italian Medicines Agency (2016) Description of Xibornol for commercial use. Available at: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000972_026642_RCP.pdf&sys=m0b1l3 (Italian language)
Knipe DM, Howley PM (eds) (2013) Fields virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
Leung HL (2021) Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol 19:528–545
doi: 10.1038/s41579-021-00535-6
pubmed: 33753932
pmcid: 7982882
Liu Q, Zhou YH, Ye F et al (2016) Antivirals for respiratory viral infections: problems and prospects. Semin Respir Crit Care Med 37(4):640–646. https://doi.org/10.1055/s-0036-1584803
doi: 10.1055/s-0036-1584803
pubmed: 27486742
pmcid: 7171711
Morandini G, Finiguerra M, Magno M (1985) Lo xibornolo nelle bronchiti. Clin Ter 112:233–239
pubmed: 4028638
Rabie AM (2021) CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy. Mol Divers 25(3):1839–1854
doi: 10.1007/s11030-020-10169-0
pubmed: 33389560
pmcid: 7778709
Rabie AM (2022) Potent inhibitory activities of the adenosine analogue Cordycepin on SARS-CoV-2 replication. ACS Omega 7(3):2960–2969
doi: 10.1021/acsomega.1c05998
pubmed: 35071937
pmcid: 8767658
Ramakrishnan MA (2016) Determination of 50% endpoint titer using a simple formula World. J Virol 5:85–86
Roth GA, Abate D, Abate KH et al (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 10:1736–1788
doi: 10.1016/S0140-6736(18)32203-7
Scaglione F, Trazzi R, Odero A et al (1988) Xibornol: multiple dose pharmacokinetics and diffusion in lung, tonsillar tissue and laryngeal mucosa. Int J Clin Pharmacol Res 8:457–461
pubmed: 3253223
Shi M, Zhao S, Yu B et al (2022) Total infectome characterization of respiratory infections in pre-COVID-19 Wuhan, China. PLoS Pathog 18(2):e1010259. https://doi.org/10.1371/journal.ppat.1010259
doi: 10.1371/journal.ppat.1010259
pubmed: 35176118
pmcid: 8853501
Templeton MR, Andrews RC, Hofmann R (2008) Particle-associated viruses in water: impacts on disinfection processes. Crit Rev Env Sc Technol 38:137–164
doi: 10.1080/10643380601174764
UNI EN 14476 (2019) European Committee for Standardization. Chemical disinfectants and antiseptics – Virucidal quantitative suspen-sion test for chemical disinfectants and antiseptics used in human medicine – Test method and requirements (phase 2 step 1)
Verani M, Federigi I, Bigini C et al (2017) Evaluation of the virucidal effect by contact with water-insoluble substances: the case of Xibornol. Int J Pharm Sci Rev Res 44:159–164
Verani M, Di Giuseppe G, Federigi I et al (2020) Preliminary data related to the effect of climacostol produced by the freshwater ciliate Climacostomum virens on human adenovirus. Viruses 12:658
doi: 10.3390/v12060658
pubmed: 32570859
pmcid: 7354546
WHO (2020) Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19: interim guidance, 29 July 2020